The increasing interest in effective weight management has led to considerable exploration into groundbreaking treatments. Currently, Retatrutide, a twin-action hormone and glucagon-like peptide-1 (GLP-1) receptor agonist , has exhibited promising results in patient trials, implying potential for considerable weight reduction . Consequently , numer